Company Overview
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Why Investors Should Care
Revenue has grown at a 70.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $37.06M (+4.1% YoY); net profit $-8.20M.
- Trailing 12 Months Year-on-year growth — revenue +0.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 70.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 70.48% |
| 1 Year: | 0.20% |
Stock Price Performance
| 1 Year: | +534.26% |
| 6 Months: | +745.78% |
| 3 Months: | +1,553.79% |
| 1 Month: | +1,802.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross1d ago
- RSI (14)95.93 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 70.5% over 5 years.
CONS
- RSI at 96 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTSO Cytosorbents Corporation PHARMA | 6.85 | -1.18 | $21.52M | 0.00% | -41.30% | - | 70.48% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.81M | 2.22M | 2.41M | 3.08M | 3.11M | 3.57M | 3.82M | 4.65M | 4.92M | 5.76M | 5.74M | 6.08M | 5.19M | 6.23M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.63M |
| Gross Profit | 990.68K | 1.35M | 1.45M | 1.79M | 1.86M | 2.08M | 2.31M | 3.38M | 3.36M | 3.97M | 3.69M | 4.00M | 3.45M | 4.40M | 4.40M | 5.34M | 6.32M | 6.55M | 7.66M | 9.43M | 7.85M | 9.31M | 7.30M | 7.66M | 6.41M | 4.94M | 3.62M | 5.76M | 5.46M | 6.02M | 5.61M | 5.31M | 6.87M | 6.50M | 5.26M | 6.21M | 6.81M | 6.67M | 6.13M | 7.05M |
| Operating Income | -2.09M | -2.69M | -2.14M | -4.57M | -1.56M | -2.33M | -2.15M | -3.81M | -3.10M | -4.19M | -2.71M | -5.59M | -4.29M | -3.63M | -5.63M | -5.43M | -2.48M | -3.30M | -1.96M | -2.63M | -2.85M | -4.92M | -5.41M | -9.56M | -7.79M | -8.36M | -9.02M | -6.36M | -7.89M | -6.56M | -7.35M | -9.41M | -4.66M | -3.57M | -4.83M | -3.89M | -3.62M | -2.86M | -3.04M | -2.64M |
| Net Income | -1.84M | -3.01M | -2.19M | - | -1.52M | -1.73M | -2.05M | - | -2.98M | -5.82M | -3.00M | - | -4.88M | -3.55M | -6.89M | - | -3.45M | -2.87M | -839.73K | - | -4.17M | -4.68M | -6.41M | - | -8.97M | -10.88M | -12.20M | - | -7.33M | -6.15M | -9.19M | - | -6.09M | -4.29M | -2.77M | -1.48M | 1.95M | -3.17M | -5.13M | -4.42M |
| Diluted EPS | - | -0.12 | - | - | - | - | - | - | - | - | - | - | -0.15 | -0.11 | -0.21 | -0.13 | -0.10 | -0.08 | -0.02 | 0.00 | -0.10 | -0.11 | -0.15 | -0.25 | -0.21 | -0.25 | -0.28 | -0.02 | -0.17 | -0.15 | -0.21 | -0.12 | -0.11 | -0.08 | -0.05 | -0.02 | 0.03 | -0.05 | -0.08 | -0.07 |
| R&D Expense | 856.12K | 1.09M | 1.17M | - | 469.55K | 458.03K | 643.19K | - | 1.73M | 1.58M | 1.94M | - | 2.42M | 2.93M | 3.19M | - | 1.97M | 2.41M | 1.75M | - | 2.28M | 3.70M | 4.26M | - | 4.24M | 4.18M | 3.29M | - | 4.21M | 3.67M | 3.75M | - | 2.25M | 1.52M | 1.85M | 1.66M | - | - | 1.02M | 1.45M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 1997 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.08K | 1.34M | 2.42M | 4.12M | 4.79M | 9.53M | 15.15M | 22.50M | 24.95M | 41.00M | - | 29.36M | 31.08M | 35.59M | 37.06M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.96M | 9.13M | 10.71M | 10.57M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.32K | 1.02M | 511.10K | 1.99M | 2.58M | 5.57M | 9.63M | 15.01M | 17.59M | 29.95M | - | 15.40M | 21.95M | 24.89M | 26.49M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.93M | 53.90M | 41.34M | 40.73M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.82M | -4.44M | -3.49M | -4.71M | -6.89M | -9.30M | -11.49M | -9.84M | -15.58M | -18.97M | -10.37M | - | -31.52M | -31.95M | -16.45M | -14.24M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.39M | -27.88M | -19.27M | -4.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 157.89K | 1.40M | 2.61M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.91M | -30.06M | -22.41M | -8.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.09M | -813.74K | -1.69M | -401.00K |
| Net Income | -5.26M | -1.87M | -10.75M | -3.07M | -15.39M | -11.87M | -6.01M | -1.10M | -3.67M | -76.72M | -3.35M | -3.02M | -2.74M | -2.91M | -5.48M | -3.66M | -4.68M | -9.32M | -9.48M | -11.76M | -8.46M | -17.21M | -19.27M | -7.84M | - | -32.81M | -29.25M | -20.72M | -8.20M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.60 | -0.20 | - | -0.75 | -0.65 | -0.38 | -0.13 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.76M | 2.89M | 2.53M | 1.74M | 2.43M | 3.87M | 4.07M | 3.22M | 7.72M | 12.09M | 8.81M | 16.38M | 15.12M | 15.73M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 1997 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.81M | 2.12M | 3.34M | 4.05M | 8.47M | 11.25M | 9.69M | 24.10M | 34.20M | 27.38M | 89.95M | 89.52M | 63.23M | 57.46M | 52.44M | 47.58M | 52.96M | 47.07M | 53.43M | 47.80M | 47.37M | 44.18M |
| Total Equity | 877.48K | 1.58M | 100.55K | 5.34M | 2.33M | -4.37M | -3.91M | -6.97M | -9.76M | 2.36M | -104.30K | -3.35M | -5.74M | -8.07M | -10.09M | -11.63M | -14.27M | 6.94M | 9.85M | 1.34M | 10.26M | 16.93M | 3.42M | 79.22M | 62.58M | 35.37M | 29.94M | 24.46M | 18.81M | 23.48M | 19.63M | 17.43M | 13.14M | 11.11M | 5.90M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | 1.60M | 1.06M | 1.19M | 1.73M | 2.18M | 3.61M | 5.32M | 5.25M | 17.32M | 22.37M | 12.23M | 71.42M | 52.14M | 22.14M | - | - | - | 14.13M | - | - | - | 3.28M | 6.25M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 4.08M | 5.99M | 9.27M | 13.39M | 0 | - | 5.00M | - | - | - | 2.54M | - | - | - | 14.00M | 16.67M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.30M | 1.80M | 2.08M | 3.06M | - | 3.04M | 8.36M | 13.84M | 17.26M | 23.96M | 10.73M | 26.94M | 27.86M | 27.52M | 27.98M | 28.76M | 29.48M | 27.44M | 36.00M | 34.66M | 36.27M | 38.28M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22M | 1.53M | 2.08M | 3.06M | 4.51M | 3.04M | 4.28M | 7.85M | 6.92M | 9.94M | 10.15M | 13.69M | 9.71M | 9.45M | 9.99M | 11.67M | 14.04M | 12.72M | 9.64M | 8.28M | 9.82M | 9.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.48M | -3.83M | -3.62M | -3.49M | -6.66M | -9.05M | -6.73M | -6.46M | -10.84M | -16.76M | -5.61M | -14.01M | -28.23M | -21.66M | -14.43M | -12.38M |
| Investing Cash Flow | -165.45K | -52.49K | -38.81K | -216.36K | -2.31M | -890.90K | 1.60M | -1.68M | -1.52M | -1.52M | -1.68M | -4.28M | -6.46M | -936.24K | -669.00K | -415.00K |
| Financing Cash Flow | 2.10M | 4.01M | 4.21M | 4.20M | 10.02M | 11.64M | 5.06M | 20.12M | 17.47M | 8.18M | 66.35M | 715.20K | 4.96M | 14.47M | 9.33M | 9.31M |
| Capital Expenditure | -139.36K | -34.67K | -19.85K | -38.68K | -153.16K | -403.61K | -140.72K | -990.67K | -671.97K | -698.16K | -708.39K | -3.64M | -6.09M | -538.12K | -284.00K | -164.00K |
| Free Cash Flow | -2.62M | -3.86M | -3.64M | -3.53M | -6.81M | -9.45M | -6.87M | -7.45M | -11.51M | -17.46M | -6.32M | -17.65M | -34.32M | -22.19M | -14.71M | -12.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 1997 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.4% | 76.2% | 21.1% | 48.2% | 53.8% | 58.5% | 63.6% | 66.7% | 70.5% | 73.0% | - | 52.5% | 70.6% | 69.9% | 71.5% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12,297.7% | -259.9% | -194.5% | -167.2% | -194.2% | -120.6% | -65.0% | -69.3% | -76.0% | -25.3% | - | -107.4% | -102.8% | -46.2% | -38.4% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15,193.9% | -272.8% | -193.1% | -226.1% | -197.8% | -123.5% | -55.8% | -76.5% | -77.2% | -19.1% | - | -111.8% | -94.1% | -58.2% | -22.1% |
| ROE % | -599.0% | -118.2% | -10,695.3% | -57.4% | -660.9% | 271.4% | 153.8% | 15.7% | 37.6% | -3,246.5% | 3,212.7% | 90.2% | 47.7% | 36.1% | 54.3% | 31.5% | 32.8% | -134.2% | -96.2% | -879.5% | -82.4% | -101.6% | -563.6% | -9.9% | - | -92.8% | -124.6% | -186.5% | -138.9% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | -476.4% | -746.2% | -276.5% | -480.5% | -173.9% | -113.3% | -212.2% | -60.6% | -57.1% | -108.8% | -13.0% | - | -58.9% | -82.1% | -43.8% | -41.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Avenir Corp | 8.23% | 259.46K | $1.49M |
| 2 | Neuberger Berman Group, LLC | 3.12% | 98.44K | $566.00K |
| 3 | Vanguard Capital Management LLC | 3.04% | 95.70K | $550.29K |
| 4 | CM Management, LLC | 2.34% | 73.83K | $424.49K |
| 5 | Skylands Capital, LLC | 1.92% | 60.57K | $348.28K |
| 6 | Blackrock Inc. | 1.00% | 31.36K | $180.32K |
| 7 | Geode Capital Management, LLC | 0.96% | 30.10K | $173.09K |
| 8 | Sargent Investment Group, LLC | 0.88% | 27.79K | $159.78K |
| 9 | Pathstone Holdings, LLC | 0.79% | 25.00K | $143.73K |
| 10 | Vanguard Fiduciary Trust Co | 0.50% | 15.81K | $90.90K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTSO
$CTSO stock is up 19% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPc0JTblZpTmZaNGl0NzBoc3pERTQxYXZrcGxaNndjN2dmTzBPckxBWnpaSFZMRlRObW5pUmwzeWVsQVBYb2EwLVdXLWw0bHZiU09XdmtDZDlUQWtPSERCVmpzMG1WX3lac3RndXc4am1UX1paNjhqX0JUUU5MZm5kXzRnc1dnSGJfbFp6Wn…
A blood-cleansing device was linked to 37% less severe bleeding in urgent heart surgery - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQQ0dLNURkRWhZNThfTTNGN1UweWo3Z0E5N2NFXzJvQk9UWkd3cU05VkRXRHlXVldyM1pqcUVnOEF4dlR5MF9fR3BVSEhvWUQ0LVhFWGF4VDhrdGl0MllCUXh5NGg0TmRUZXdRZS1iVFFidUFOVkdvd0VPb1loUVAyY1VnZnhCcTZSTEdTTV…
CytoSorbents Announces Reverse Stock Split - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxONjd6TEFSbHNyRzV3WlluaUJ1U0lJX2dMNzZUNjBuUkhoQ2IxckxJbXluTXp6b0VidFdjcG1PSVotRF8wYnVMSmZmNDkxTXlmcnZ0M2REQ3NGN3JmcmNBNUluTklZdm1kRTJJaXdXVDlXUUVfNkU1bFAyN0VYVlpUdjgzVXhldFpBZ3VmMm…
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM - Bitget
<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE50WjRWYUNlT3ctejZwWEVrMHdjUkpzVndzcHVJVkZpdEZLYTVXd3B0b1RBM084amUycHhXeHItSUYwUnFRc2ZDZ0daTHRqVm9oeEpJREZ6R01qc1FrSjVRZFlWa9IBY0FVX3lxTE50WjRWYUNlT3ctejZwWEVrMHdjUkpzVndzcHVJVkZpdE…
Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQX1BpYWlJakpaOC16UlZ4SC1rcGhlTHVETzZCZnBlTWU3TGRxZ0dMMEQ1a2ZFTC1pMHNiOWpjb2owbkxMUGFxRUhSR3BfMGFzc2s0MnB5dnJMWmg0ZXd2anc5c1lERG92SzNCODc2VTVlOTFYWU9kQThhQ2gwQ1ZDdWV6NWdKaGVjaS12RE…
Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNUUwwVFhzcUZHZnhCYmh6NFl1VFNob3BpLXF2Y25IWml6MVczXzhkcmxEWDFhUHVjTGFfVjBGWUEwa1ViaG5RS0lVNzE0N1hzaFVJa2dmYlBXZi1WV3U1UzVJS2REa1ZuM3FXVENrbE5GRVEtX01STV9XMmFsMTZTc184NzV4TF83bFNGYk…
CTSO — Frequently Asked Questions
What is the current share price of Cytosorbents Corporation (CTSO)?
As of 2026-09-19 21:16 PDT, Cytosorbents Corporation (CTSO) trades at $6.85 on NasdaqCM. Its 52-week range is $0.31 to $7.00.
What is the market capitalisation of CTSO?
Cytosorbents Corporation (CTSO) has a market capitalisation of $21.52M on NasdaqCM.
What is the P/E ratio of CTSO?
CTSO trades at a trailing price-to-earnings (P/E) ratio of -1.18. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -26.49.
Is CTSO a good stock to buy?
This page provides a data-driven analysis of Cytosorbents Corporation (CTSO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.